A Multicenter, Phase II, Randomized, Open Label Trial of 2 Dose Levels of RTA 402 [CDDO-Me] in Patients With Advanced Malignant Melanoma

Trial Profile

A Multicenter, Phase II, Randomized, Open Label Trial of 2 Dose Levels of RTA 402 [CDDO-Me] in Patients With Advanced Malignant Melanoma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2014

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 10 Dec 2007 Status changed from initiated to withdrawn prior to recruitment. This study was withdrawn prior to recruitment.
    • 05 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top